Processa Pharmaceuticals Schedules Conference Call to Discuss First Quarter Results and Provide Drug Development Update on Ma...
May 07 2021 - 8:30AM
Processa Pharmaceuticals, Inc. (NASDAQ: PCSA), (“Processa” or the
“Company”), a clinical-stage biopharmaceutical company developing
products to improve the survival and/or quality of life for
patients who have unmet medical needs, today announces it will host
a conference call and live
webcast on May 13, 2021, at 5:30 p.m.
EST to discuss its first quarter 2021 results and provide an update
on the Company’s clinical pipeline.
Conference Call Information
To participate in this event, please dial in
approximately 5 to 10 minutes before the beginning of the call.
Date: May 13, 2021Time: 5:30 p.m. ETToll Free: 888-506-0062;
Entry Code: 396394International: 973-528-0016; Entry Code:
396394
Live Webcast:
https://www.webcaster4.com/Webcast/Page/2572/41274
Conference Call Replay Information
Toll-free: 877-481-4010International: 919-882-2331Replay
Passcode: 41274
About Processa Pharmaceuticals, Inc.
The mission of Processa is to develop products
with existing clinical evidence of efficacy for patients with unmet
or underserved medical conditions who need treatment options that
improve survival and/or quality of life. The Company uses these
criteria for selection to further develop its pipeline programs to
achieve high-value milestones effectively and efficiently. Active
clinical pipeline programs include: PCS6422 (metastatic colorectal
cancer and breast cancer), PCS499 (ulcerative necrobiosis
lipoidica) and PCS12852 (GI motility/gastroparesis). The members of
the Processa development team have been involved with more than 30
drug approvals by the FDA (including drug products targeted to
orphan disease conditions) and more than 100 FDA meetings
throughout their careers. For more information, visit the company’s
website at www.ProcessaPharma.com .
Forward-Looking Statements
This release contains forward-looking
statements. The statements in this press release that are not
purely historical are forward-looking statements which involve
risks and uncertainties. Actual future performance outcomes and
results may differ materially from those expressed in
forward-looking statements. Please refer to the registration
statement relating to the securities being sold in this offering,
which identifies important risk factors which could cause actual
results to differ from those contained in the forward-looking
statements.
For More Information:Michael
Floydmfloyd@processapharma.com301-651-4256
James CarbonaraHayden IR(646)
755-7412james@haydenir.com
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Aug 2024 to Sep 2024
Processa Pharmaceuticals (NASDAQ:PCSA)
Historical Stock Chart
From Sep 2023 to Sep 2024